These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 21446639)
1. Update on newer antipsychotic drugs. Howland RH J Psychosoc Nurs Ment Health Serv; 2011 Apr; 49(4):13-5. PubMed ID: 21446639 [TBL] [Abstract][Full Text] [Related]
2. Iloperidone, asenapine and lurasidone: a primer on their current status. Tarazi FI; Stahl SM Expert Opin Pharmacother; 2012 Sep; 13(13):1911-22. PubMed ID: 22849428 [TBL] [Abstract][Full Text] [Related]
3. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950 [TBL] [Abstract][Full Text] [Related]
4. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Bobo WV Expert Rev Clin Pharmacol; 2013 Jan; 6(1):61-91. PubMed ID: 23272794 [TBL] [Abstract][Full Text] [Related]
5. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Citrome L Postgrad Med; 2011 Mar; 123(2):153-62. PubMed ID: 21474903 [TBL] [Abstract][Full Text] [Related]
6. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Pae CU Clin Neuropharmacol; 2013; 36(6):223-38. PubMed ID: 24201235 [TBL] [Abstract][Full Text] [Related]
7. Newer antipsychotics and upcoming molecules for schizophrenia. George M; Amrutheshwar R; Rajkumar RP; Kattimani S; Dkhar SA Eur J Clin Pharmacol; 2013 Aug; 69(8):1497-509. PubMed ID: 23545936 [TBL] [Abstract][Full Text] [Related]
8. New drugs: asenapine, iloperidone, and bepotastine besilate. Hussar DA; Abbas CA J Am Pharm Assoc (2003); 2010; 50(1):107-10. PubMed ID: 20097650 [No Abstract] [Full Text] [Related]
9. Biological perspectives: update on newer antipsychotic drugs: are they evidence based? Keltner NL; Moore RL; Grant JS Perspect Psychiatr Care; 2011 Oct; 47(4):220-6. PubMed ID: 21950369 [No Abstract] [Full Text] [Related]
10. Iloperidone (Fanapt) - a new indication for bipolar disorder. Med Lett Drugs Ther; 2024 Jul; 66(1707):115-116. PubMed ID: 39008105 [No Abstract] [Full Text] [Related]
11. Lurasidone (Latuda) for schizophrenia. Med Lett Drugs Ther; 2011 Feb; 53(1358):13-4. PubMed ID: 21372761 [No Abstract] [Full Text] [Related]
12. Atypical antipsychotics: the two new arrivals. Roman MW Issues Ment Health Nurs; 2011; 32(1):85-6. PubMed ID: 21208056 [No Abstract] [Full Text] [Related]
14. Asenapine (Saphris) sublingual tablets for schizophrenia and bipolar disorder. Med Lett Drugs Ther; 2010 Feb; 52(1331):9-10. PubMed ID: 20216523 [No Abstract] [Full Text] [Related]
15. Iloperidone for the management of adults with schizophrenia. Crabtree BL; Montgomery J Clin Ther; 2011 Mar; 33(3):330-45. PubMed ID: 21600386 [TBL] [Abstract][Full Text] [Related]
16. Lurasidone: a new treatment option for schizophrenia. Owen RT Drugs Today (Barc); 2011 Nov; 47(11):807-16. PubMed ID: 22146224 [TBL] [Abstract][Full Text] [Related]
17. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia]. Samalin L; Ben Gharbia M; Garnier M; Llorca PM Encephale; 2014 Dec; 40(6):507-17. PubMed ID: 25453735 [TBL] [Abstract][Full Text] [Related]
18. Asenapine: a clinical review of a second-generation antipsychotic. Stoner SC; Pace HA Clin Ther; 2012 May; 34(5):1023-40. PubMed ID: 22494521 [TBL] [Abstract][Full Text] [Related]